BridgeBio Oncology Therapeutics, Inc. (BBOT)
NasdaqGM · USD · Healthcare · Biotechnology
$2.64 (-0.75%) as of
Key statistics
- Market cap
- 211.66M
- Forward P/E
- -0.96
- EPS (TTM)
- -0.0700
- Dividend yield
- 0.00%
- 52-week range
- 2.6000 – 14.8700
- Beta
- 0.65
- Profit margin
- 0.00%
- Analyst target
- $23.55
- Volume
- 483.08k
About BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- South San Francisco, CA, United States
- Employees
- 88
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.